PharmaCorp Rx Inc.
PCRX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 349.47% | 1,004.35% | 601.13% | 105.01% | 900.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1,520.83% | 1,584.89% | 822.68% | 105.01% | 900.56% |
| Operating Income | 243.68% | -746.58% | -522.68% | -105.01% | -900.56% |
| Income Before Tax | 377.03% | -852.39% | -744.94% | -141.09% | -8,263.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 425.17% | -853.19% | -744.75% | -141.09% | -8,263.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 441.35% | -851.46% | -747.08% | -141.09% | -8,263.16% |
| EBIT | 243.68% | -746.58% | -522.68% | -105.01% | -900.56% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 158.97% | -70.27% | -212.00% | -138.71% | -7,700.00% |
| Normalized Basic EPS | 153.06% | -69.57% | -206.25% | -142.11% | -4,800.00% |
| EPS Diluted | 158.97% | -70.27% | -212.00% | -138.71% | -7,700.00% |
| Normalized Diluted EPS | 153.06% | -69.57% | -206.25% | -142.11% | -4,800.00% |
| Average Basic Shares Outstanding | 479.64% | 458.02% | 174.39% | 0.39% | 1.39% |
| Average Diluted Shares Outstanding | 479.64% | 458.02% | 174.39% | 0.39% | 1.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |